Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
Maju Mathews,1 Isaac Nuamah,1 Adam J Savitz,1 David W Hough,1 Dean Najarian,2 Edward Kim,2 Srihari Gopal1 1Janssen Research and Development, LLC, Titusville, NJ, USA; 2Janssen Scientific Affairs, Titusville, LLC, NJ, USA Objective: The aim of this study was to evaluate the safety of 3-monthly pali...
Main Authors: | Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | Neuropsychiatric Disease and Treatment |
Subjects: | |
Online Access: | https://www.dovepress.com/time-to-onset-and-time-to-resolution-of-extrapyramidal-symptoms-in-pat-peer-reviewed-article-NDT |
Similar Items
-
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
by: Mathews M, et al.
Published: (2020-06-01) -
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019-05-01) -
Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019-06-01) -
A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
by: Jie Liu, et al.
Published: (2022-02-01) -
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
by: Li G, et al.
Published: (2021-10-01)